ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...
NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder cancer with papillary only disease. This update extends recognized use of ...
ImmunityBio (IBRX) stock jumped over 6% in premarket trading after the NCCN added ANKTIVA to its bladder cancer guidelines, expanding its use.
Asianet Newsable on MSN
Why did IBRX stock jump 7% in pre-market today?
The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved.
ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, Anktiva. Read more here.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...
Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as an initial treatment option for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...
Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have ...
Distress management guideline updates aim to destigmatize the psychosocial effects of cancer and treatment, and encourage patients with cancer to seek help.
New research suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results